Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Trial status:Recruiting
Study Identifier:
BNT142-01
ClinicalTrials.gov Identifier:
NCT05262530
EudraCT Identifier:
2021-005481-18
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting

Trial details

Medical Condition
  • Solid Tumors
    • Study Drug
  • Biological: BNT142
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+
    Estimated Trial Date
    Mar 2022 - Oct 2025

    Protocol summary

    This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.

    Trial locations

    Location
    Status
    Location
    Indiana University School of Medicine
    Indianapolis, Indiana, United States, 46202
    Status
    Not yet recruiting
    Location
    University of Maryland Medical Center
    Baltimore, Maryland, United States, 21201
    Status
    Recruiting
    Location
    Memorial Sloan Kettering Cancer Center
    New York, New York, United States, 10065
    Status
    Not yet recruiting
    Location
    Duke University Medical Center
    Durham, North Carolina, United States, 27705
    Status
    Recruiting
    Location
    University of Pennsylvania
    Philadelphia, Pennsylvania, United States, 19104
    Status
    Recruiting
    Location
    The University of Texas MD Anderson Cancer Center
    Houston, Texas, United States, 77030
    Status
    Recruiting